Scholarlink

Background <p>Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for cT2-4aN0M0 bladder cancer (BCa) patients candidates for radical cystectomy (RC). This study examines changes in NAC administration over time and its impact on survival within a large, real-world multicenter cohort.</p> Methods <p>Our analysis included cT2-4aN0M0 BCa patients from 23 tertiary referral centers who underwent RC and pelvic lymph-node dissection with or without NAC administration between 2004 and 2024. The estimated annual percentage change (EAPC) was used to analyze the temporal trend of NAC administration and pathological complete response rates (pT0) over time. Subsequently, we relied on 1:1 propensity score matching (PSM) for age, sex, cT stage, Charlson Comorbidity Index (CCI), and smoking habit. Multivariable logistic regression (MLR) model addressed the association of pT0 and NAC exposure. Survival analyses consisted of Kaplan–Meier plots (KM) and multivariable Cox regression models (MCR) addressing cancer-specific mortality (CSM) and overall mortality (OM) according to NAC exposure.</p> Results <p>Overall, 3,138 patients were identified. Of these, 859 (27%) received NAC. NAC implementation increased substantially from 2004 to 2024 (EAPC: + 9.2%, p &lt; 0.001), as well as pT0 rates (EAPC: + 7.6, p &lt; 0.001). After 1:1 PSM (847 NAC + vs. 847 NAC–), MLR showed NAC as the strongest predictor of pT0 (OR: 2.89, p &lt; 0.001). KM estimated 5-year CSM and OM rates of 22.5% versus 31.3% and 23.6 versus 34.5% in NAC + versus NAC-, respectively.At MCR, NAC exposure was associated with lower CSM (HR: 0.90, p = 0.01) and OM (HR:0.85, p = 0.001) rates relative to their unexposed counterparts.</p> Conclusions <p>The current study demonstrated a significant increase in NAC administration over time, accompanied by higher rates of pT0 as well as improved survival among NAC-treated patients. The major limitation is represented by the retrospective nature of the study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year study

  • 期刊论文

  • 发表日期：

    2025年10月28日

查看全文
  • Mario de Angelis,
  • Francesco Pellegrino,
  • Pietro Scilipoti,
  • Mattia Longoni,
  • Alfonso Santangelo,
  • José Daniel Subiela,
  • Roberto Contieri,
  • Luca Afferi,
  • Stefania Zamboni,
  • Nazareno Suardi,
  • Gennaro Musi,
  • Stefano Luzzago,
  • David D’Andrea,
  • Ekaterina Laukhtina,
  • Francesco Soria,
  • Paolo Gontero,
  • Francesco Del Giudice,
  • Muhammad Shamim Khan,
  • Ramesh Thurairaja,
  • Morgan Roupret,
  • Elisabeth Grobet-Jeandin,
  • Arthur Baudewyns,
  • Hajime Tanaka,
  • Shunya Matsumoto,
  • Yasuhisa Fujii,
  • Flavia Proietti,
  • Giuseppe Simone,
  • Gerald Bastian Schulz,
  • Nicolaos Pyrgidis,
  • Guillaume Ploussard,
  • Alessandro Antonelli,
  • Riccardo Bertolo,
  • Mathieu Roumiguie,
  • Anne-Sophie Bajeot,
  • Maria Carme Mir,
  • Paolo Umari,
  • Jeremy Teoh,
  • Chris Wong,
  • Laura S. Mertens,
  • Renate Pichler,
  • Keiichiro Mori,
  • Aleksander Ślusarczyk,
  • Cédric Poyet,
  • Simone Albisinni,
  • Atiqullah Aziz,
  • Alessandro Volpe,
  • Shahrokh Shariat,
  • Benjamin Pradere,
  • Pierre Karakiewicz,
  • Stefano Resca,
  • Edoardo Beatrici,
  • Ruben De Groote,
  • Alexandre Mottrie,
  • Andrea Necchi,
  • Francesco Montorsi,
  • Alberto Briganti,
  • Marco Moschini

摘要

Background

Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for cT2-4aN0M0 bladder cancer (BCa) patients candidates for radical cystectomy (RC). This study examines changes in NAC administration over time and its impact on survival within a large, real-world multicenter cohort.

Methods

Our analysis included cT2-4aN0M0 BCa patients from 23 tertiary referral centers who underwent RC and pelvic lymph-node dissection with or without NAC administration between 2004 and 2024. The estimated annual percentage change (EAPC) was used to analyze the temporal trend of NAC administration and pathological complete response rates (pT0) over time. Subsequently, we relied on 1:1 propensity score matching (PSM) for age, sex, cT stage, Charlson Comorbidity Index (CCI), and smoking habit. Multivariable logistic regression (MLR) model addressed the association of pT0 and NAC exposure. Survival analyses consisted of Kaplan–Meier plots (KM) and multivariable Cox regression models (MCR) addressing cancer-specific mortality (CSM) and overall mortality (OM) according to NAC exposure.

Results

Overall, 3,138 patients were identified. Of these, 859 (27%) received NAC. NAC implementation increased substantially from 2004 to 2024 (EAPC: + 9.2%, p < 0.001), as well as pT0 rates (EAPC: + 7.6, p < 0.001). After 1:1 PSM (847 NAC + vs. 847 NAC–), MLR showed NAC as the strongest predictor of pT0 (OR: 2.89, p < 0.001). KM estimated 5-year CSM and OM rates of 22.5% versus 31.3% and 23.6 versus 34.5% in NAC + versus NAC-, respectively.At MCR, NAC exposure was associated with lower CSM (HR: 0.90, p = 0.01) and OM (HR:0.85, p = 0.001) rates relative to their unexposed counterparts.

Conclusions

The current study demonstrated a significant increase in NAC administration over time, accompanied by higher rates of pT0 as well as improved survival among NAC-treated patients. The major limitation is represented by the retrospective nature of the study.